Company intelligence / Profile preview

Vivek Ramaswamy

New York, New York, United Statesvivek2024.com ↗

Ownership: Private
Employees: ~908
Development stage: Phase 3

Overview

Roivant has had mixed clinical results. Notable successes include the TL1A drug that was sold to Roche for over $7 billion. Notable failures include intepirdine for Alzheimer's disease through its Axovant subsidiary, which failed in clinical trials in 2017.

Therapeutic areas: Men's HealthPulmonologyImmunologyRare DiseasesHematologyDermatologyGastroenterologyCardiovascularNeurologyWomen's Health
Modalities: Small moleculesmonoclonal antibodiesgene therapiesenzyme replacement therapiesregenerative therapiesRNA-based therapeuticsdrug-device combinations
Industry: Biotech

Drug pipeline

1 asset

intepirdine

Failed Phase 3

Indications: Alzheimer's disease

Partnerships

Sumitomo Dainippon Pharma ($3 billion partnership)PfizerCITIC Group

Beyond the preview

Go deeper on Vivek Ramaswamy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivek Ramaswamy.

Explore the full profile